Recent neuroimaging and cellular studies link long COVID to structural damage in the dopamine system rather than widespread brain inflammation. Researchers are now exploring whether these changes, which mirror aspects of neurodegenerative disease, could be treated with dopamine-targeting therapies.

A novel delivery method leverages the glymphatic system to transport genetic material to glial cells, bypassing the blood-brain barrier. This approach aims to reduce systemic toxicity while providing a method for treating neurodegenerative conditions.

A recent study suggests that maintaining a brisk walking pace in one's eighties could be a powerful indicator of cognitive resilience. Researchers are investigating how these 'super movers' maintain sharp mental function despite potential signs of brain pathology.

The subcutaneous infusion therapy Vyalev offers a non-invasive alternative to traditional Parkinson's treatments by maintaining steady medication levels. Real-world data show symptom reduction alongside challenges regarding treatment retention.